Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of pomalidomide monotherapy in children and young adults with recurrent or progressive primary brain tumors
2016-002903-25Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- May 2017
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pomalidomide in brain neoplasm, medulloblastoma, ependymoma and 2 more (4 cohorts), sponsored by Celgene Corporation. Primary endpoint: Objective response and long-term stable disease rate. Started May 2017; status: completed.
02
Drugs
pomalidomide
03
Conditions
brain neoplasmmedulloblastomaependymomadiffuse intrinsic pontine glioma (DIPG)primary brain neoplasm
Beyond the preview
Go deeper on 2016-002903-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002903-25.